To read the full story, subscribe or sign in.

Algeta board backs new $2.9B bid from Bayer

Dec. 20, 2013

Bowing to the inevitable, the board of Algeta ASA voted unanimously to recommend a sweetened NOK362-per-share bid from Bayer AG, which values the company at NOK17.6 billion (US$2.9 billion).

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...